Bristol-Myers Squibb: Arthritis, Rheumatoid trials

The registry lists 92 Arthritis, Rheumatoid studies with Bristol-Myers Squibb as lead sponsor. 4 are open to participants now and 32 have results posted.

Phase 1 22Phase 2 14Phase 3 24Phase 4 2No phase 34(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of BMS-986553 in Participants With Refractory Autoimmune DiseasesNot yet recruitingNCT07873931Phase 1
• A Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisRecruitingNCT07412704Phase 1/2
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisRecruitingNCT07171983Phase 1
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesRecruitingNCT07115745Phase 1
• A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateActive, not recruitingNCT04909801Phase 3Results posted
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCompletedNCT04186871Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different ProcessesCompletedNCT03714022Phase 1Results posted
• Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT02638948Phase 2Results posted
• Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisCompletedNCT02557100Phase 4Results posted
• Effects of Abatacept in Patients With Early Rheumatoid ArthritisCompletedNCT02504268Phase 3Results posted
• Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled SyringeCompletedNCT01890473Phase 1Results posted
• Methotrexate-Inadequate Response Autoinjector Device Sub StudyCompletedNCT01844895Phase 3Results posted
• Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers SquibbCompletedNCT01439204Phase 1Results posted
• Methotrexate - Inadequate Response Device Sub-StudyCompletedNCT01173120Phase 3Results posted
• Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid ArthritisCompletedNCT01142726Phase 3Results posted
• Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese PatientsCompletedNCT01001832Phase 2/3Results posted
• Substudy - Low Dose of Abatacept in Subjects With Rheumatoid ArthritisCompletedNCT00989235Phase 3Results posted
• Abatacept Versus Adalimumab Head-to-HeadCompletedNCT00929864Phase 3Results posted
• A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler UltrasonographyCompletedNCT00767325Phase 3Results posted
• Phase IIIB Switching From Intravenous to Subcutaneous StudyCompletedNCT00663702Phase 3Results posted
• Methotrexate-Inadequate Response StudyCompletedNCT00559585Phase 3Results posted
• Phase IIIB Subcutaneous Abatacept Monotherapy StudyCompletedNCT00547521Phase 3Results posted
• Phase IIIB Subcutaneous Missed Dose StudyCompletedNCT00533897Phase 3Results posted
• A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid ArthritisCompletedNCT00484289Phase 3Results posted
• A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to MethotrexateCompletedNCT00420199Phase 3Results posted
• A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateCompletedNCT00409838Phase 3Results posted
• Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)CompletedNCT00254293Phase 1/2Results posted
• Abatacept With Methotrexate- Phase IIBCompletedNCT00162266Phase 2Results posted
• Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyCompletedNCT00124982Phase 3Results posted
• Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult PatientsCompletedNCT00124449Phase 2Results posted
• Remission and Joint Damage Progression in Early Rheumatoid ArthritisCompletedNCT00122382Phase 3Results posted
• BMS-188667 in Children and Adolescents With Juvenile Rheumatoid ArthritisCompletedNCT00095173Phase 3Results posted
• Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid ArthritisCompletedNCT00095147Phase 3Results posted
• A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid ArthritisCompletedNCT00048932Phase 3Results posted
• Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.CompletedNCT00048581Phase 3Results posted
• A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to MethotrexateCompletedNCT00048568Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisActive, not recruitingNCT06025578Phase 3
• A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Active, not recruitingNCT05869955Phase 1
• A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish DatabaseCompletedNCT05421442
• A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) RegisterCompletedNCT05413044
• Safety Study of Abatacept in Rheumatoid Arthritis ParticipantsCompletedNCT03696173
• A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic AgentsCompletedNCT03670667
• Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in AustraliaCompletedNCT03663829
• A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid ArthritisCompletedNCT03457792
• The Value of Orencia in Rapidly Progressing Rheumatoid ArthritisCompletedNCT03331393
• Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)CompletedNCT03274141
• The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCompletedNCT03262740Phase 1
• A Study of BMS-986195 in Healthy Male SubjectsCompletedNCT03245515Phase 1
• A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) AbataceptCompletedNCT03188081
• Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinCompletedNCT03131973Phase 1
• A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe SubstratesCompletedNCT02762123Phase 1
• Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice SettingsCompletedNCT02758769
• Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy SubjectsCompletedNCT02705989Phase 1
• Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU CountriesCompletedNCT02632890
• Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mgCompletedNCT02600468
• Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mLCompletedNCT02600455
• Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South AfricaCompletedNCT02598466
• Safety Profile of Nulojix in Home Infusion SettingsCompletedNCT02500498
• Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy PatientsCompletedNCT02456844Phase 1
• Factors Associated With Biologic DMARD SwitchingCompletedNCT02346942
• Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in TaiwanCompletedNCT02335606
• A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male SubjectsCompletedNCT02211469Phase 1
• Post-marketing Study Assessing the Long-Term Safety of AbataceptCompletedNCT02169544
• Long Term Experience With Abatacept in Routine Clinical PracticeCompletedNCT02109666
• Long-term Experience With Abatacept SC in Routine Clinical PracticeCompletedNCT02090556
• Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life SettingCompletedNCT02037737
• Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid ArthritisCompletedNCT01975610Phase 2
• Abatacept Post-marketing Clinical Study in JapanCompletedNCT01758198Phase 4
• Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort StudyWithdrawnNCT01694693
• Korean Post-marketing Surveillance for Orencia®CompletedNCT01583244
• Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid ArthritisCompletedNCT01404585Phase 2
• Safety Study of Abatacept to Treat Rheumatoid ArthritisCompletedNCT01247766
• Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of AbataceptWithdrawnNCT01221636Phase 1
• Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on BiologicsCompletedNCT01166620
• Dose Escalation With Remicade® and Orencia®CompletedNCT01141413
• Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis PatientsCompletedNCT01137851
• Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic AgentsCompletedNCT01137838
• Predictors of Adherence to OrenciaCompletedNCT01136707
• Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)CompletedNCT01136694
• Safety Study of Abatacept in SwedenCompletedNCT01094795
• Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)Active, not recruitingNCT01088360
• Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)CompletedNCT01088321
• Abatacept Pregnancy Exposure RegistryCompletedNCT01087125
• Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)CompletedNCT01017367Phase 2
• Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT00639834Phase 1
• PoC in Rheumatoid Arthritis With MethotrexateCompletedNCT00605735Phase 2
• A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving MethotrexateCompletedNCT00345748Phase 2
• Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid ArthritisCompletedNCT00279760Phase 1/2
• Vaccination Study of Abatacept (BMS-188667) for Normal Healthy VolunteersCompletedNCT00279734Phase 1
• Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate BackgroundCompletedNCT00162292Phase 1
• The Study of Abatacept in Combination With EtanerceptCompletedNCT00162279Phase 2
• An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF TherapyCompletedNCT00162201Phase 1